Howard W Robin sold $1.2M of NKTR
President & CEO at NEKTAR THERAPEUTICS. 20,000 shares at an average of $60.75, traded Jun 16, 2026, filed Jun 18, 2026.
Score components
- +25RoleCEO
- +25Trade size$1.2M at market
- +10Share of holdings soldSold 27% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-276236, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 16, 2026 | SOpen-market sale Common Stock10b5-1 | -5,303 | $59.97 | $318k | 69,742 | Jun 18, 2026 |
| Jun 16, 2026 | SOpen-market sale Common Stock10b5-1 | -4,697 | $60.71 | $285k | 65,045 | Jun 18, 2026 |
| Jun 17, 2026 | SOpen-market sale Common Stock10b5-1 | -5,500 | $60.81 | $334k | 59,545 | Jun 18, 2026 |
| Jun 17, 2026 | SOpen-market sale Common Stock10b5-1 | -4,500 | $61.65 | $277k | 55,045 | Jun 18, 2026 |
Related signals
Other insiders at NEKTAR THERAPEUTICS and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $30k 418 shares | -1% | |
| 23Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $13k 186 shares | -2% | |
| 29Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $398k 5,681 shares | -37% | |
| 28Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $336k 5,538 shares | -26% | |
| 38Weak | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $29k 444 shares | -1% | |
| 23Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $13k 199 shares | -1% | |
| 38Weak | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $31k 423 shares | -1% | |
| 23Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $13k 180 shares | -1% | |
| 11Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $138k 3,867 shares | -15% | |
| 50Moderate | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $120k 2,207 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.